Otenabant
Chemical compound
- none
- 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(ethylamino)piperidine-4- carboxamide
- 686344-29-6
Y
- 10052040
- 8227602
N
- J8211Y53EF
- D09362 Y
- ChEMBL562668 N
- DTXSID20988316
- Interactive image
- CCNC1(CCN(CC1)C2=NC=NC3=C2N=C(N3C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl)C(=O)N
InChI
- InChI=1S/C25H25Cl2N7O/c1-2-31-25(24(28)35)11-13-33(14-12-25)22-20-23(30-15-29-22)34(17-9-7-16(26)8-10-17)21(32-20)18-5-3-4-6-19(18)27/h3-10,15,31H,2,11-14H2,1H3,(H2,28,35)N
- Key:UNAZAADNBYXMIV-UHFFFAOYSA-NN
N
Y (what is this?) (verify)Otenabant (CP-945,598) is a drug that acts as a potent and highly selective CB1 antagonist.[1] It was developed by Pfizer for the treatment of obesity,[2] but development for this application has been discontinued following the problems seen during clinical use of the similar drug rimonabant.[3]
See also
- Cannabinoid receptor antagonist
References
- ^ Kim MA, Yun H, Kwak H, Kim J, Lee J (2008). "Design, chemical synthesis, and biological evaluation of novel triazolyl analogues of taranabant (MK-0364), a cannabinoid-1 receptor inverse agonist". Tetrahedron. 64 (48): 10802–10809. doi:10.1016/j.tet.2008.09.057.
- ^ Woods SC (November 2007). "The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction". Journal of the American Academy of Physician Assistants. Suppl Endocannabinoid (11): 7–10. doi:10.1097/01720610-200711000-00005. PMID 18047036. S2CID 25472128.
- ^ "Pfizer Pharmaceutical News and Media - Pfizer: One of the world's premier biopharmaceutical companies". www.pfizer.com.
- v
- t
- e
Antiobesity agents/Anorectics (A08)
antagonists
- Drinabant§
- Ibipinabant§
- Otenabant§
- Rimonabant‡
- Rosonabant§
- Surinabant§
- Taranabant§
glucagon agonists
receptor agonists
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
